Navigation Links
Baxter Announces Licensing Agreement for Innocoll's Gentamicin Surgical Implant in the United States
Date:8/25/2008

support a planned 2009 New Drug Application for U.S. regulatory approval.

"We look forward to making this product available for surgeons to help alleviate the burden of infections occurring from surgery. A gentamicin surgical implant complements Baxter's surgical portfolio of products for hemostasis and tissue sealing," said Ron Lloyd, vice president and general manager of Baxter's BioSurgery business.

Baxter is a global, diversified healthcare company with many specialty biologic products used in surgical settings for hemostasis, tissue sealing, tissue fixation and adhesion reduction. Innocoll, a privately held biopharmaceutical company, focuses on targeted biodegradable surgical implants and topical products to reduce infection.

"We are very pleased to announce this agreement with Baxter, a recognized market leader in specialty biologics," said Dr. Michael Myers, Innocoll chief executive officer. "We look forward to establishing a strong partnership with Baxter as we prepare for NDA filing and subsequent launch in the U.S. market."

Under the terms of the agreement, Baxter will pay a license fee and will make contingent clinical, regulatory and commercial milestone payments. Baxter will also contribute to the Phase III clinical costs and a portion of the registration fees. Innocoll will be responsible for the continued management of the clinical programs and the regulatory filing. Innocoll will manufacture and supply product to Baxter. In accordance with generally accepted accounting principles, Baxter expects to record a pre-tax charge of approximately $12 million for in-process research and development associated with this transaction in the third quarter of 2008.

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. It develops and manufactures a range of pharmaceutical products and medical devices using its propr
'/>"/>

SOURCE Baxter Healthcare Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Baxter Declares Quarterly Dividend
2. Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
3. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
4. Baxters Board of Directors Declares Quarterly Dividend
5. Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
6. Baxters V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals
7. Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients
8. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
9. Baxter and Its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs Locally and Globally
10. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
11. Baxter Declares Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)COPENHAGEN, Dec. 2 The world,s first concept demonstration tires made with BioIsoprene technology, a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of
(Date:12/2/2009)CAMBRIDGE, Mass., Dec. 2 TechConnect World, an event bringing together the leaders in technology development and product integration in cleantech, nanotech, biotech and MEMS, announced the December 1
(Date:12/2/2009)QUEBEC CITY, Dec. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today annou
(Date:12/1/2009)INCLINE VILLAGE, Nev., Dec. 1 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced revenue guidance for the fourth quarter ended December 31, 2009 of approximately $57 million, as compared with
Breaking Biology Technology:The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
...e and Introduces Q1 2008 Guidance, FRAZER, Pa., F...ed 2007 sales of $1.727 billion, compared to sales...,s previously issued,guidance. Basic loss per comm...ng the previously announced settlement reserve, am...adjusted income per common share for the,full year...
... Technology Leadership, INDIANAPOLIS, Feb. 12 Th...wholly owned subsidiary of The Dow Chemical,Compan...ade to investors,earlier today by Jerome Peribere,...as speaking at the Goldman Sachs Agricultural Chem...rced Dow AgroSciences,technology-based strategy of...
...Corporation (NYSE: CBM ) announced that it will r... results on Thursday, February 14, 2008 after,mark.../prnh/20000613/CAMBREXLOGO ), The Company will h...r,and full year 2007 financial results., ...s Conference Call, When: Friday, Februa...
Other Biology Technology:Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 2Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 3Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 4Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 5Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 6Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 7Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 8Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 9Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 10Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 11Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 12Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 13Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 14Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 15Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 16Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 17Dow AgroSciences' Success Presented to Wall Street 2
(Date:12/3/2009)Have you ever felt overly upset by a social snubbing? Your genetics, not your friends, may be at fault. , Scientists have long known that opium-like painkillers, called opioids, relieve not only phys
(Date:12/3/2009)Spanish researchers have measured CO2 levels for the past three years in the troposphere (lower atmosphere) over a sparsely inhabited rural area near Valladolid. The results, which are the first of th
(Date:12/3/2009)UPTON, NY A team of scientists from the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Harvard University, and the Indian Institute of Science has made a major step in understandin
Breaking Biology News(10 mins):CO2 levels rising in troposphere over rural areas 2Grooving down the helix 2Grooving down the helix 3Power Plate 28R 29 Opens Cutting Edge Studio in L A 49383 1Power Plate 28R 29 Opens Cutting Edge Studio in L A 49383 2Benefit of glinides is not proven 49380 1Benefit of glinides is not proven 49380 2Benefit of glinides is not proven 49380 37th annual 5BBC 5D2 Basel Computational Biology Conference Molecular Evolution June 18 19 2009 8899 17th annual 5BBC 5D2 Basel Computational Biology Conference Molecular Evolution June 18 19 2009 8899 27th annual 5BBC 5D2 Basel Computational Biology Conference Molecular Evolution June 18 19 2009 8899 3
...e investigating exactly how chemotherapy drugs kil...s and test the effectiveness of safer new agents. ...versity of Manchester,s Faculty of Life Sciences h...ti-mitotic drugs, which are used extensively for b...f drugs, which includes the agent taxol, has been ...
...imate change, researchers at BBSRC-supported Rotha...amaging aphids the peach-potato aphid (Myzus pers...er for every 1C rise in mean temperature for Janua...hid was caught on 25 April, which is almost four w...eported in BBSRC Business, the quarterly researc...
...erated in health care, computational biology, home... massive and unstructured data sets has proven cum...known as data and visual analytics is helping sift... put together individual pieces of a picture. , T...five-year grant to lead and coordinate a new initi...
Other Biology News:How chemo kills tumors: research to reduce side effects 2How chemo kills tumors: research to reduce side effects 3Aphids are sentinels of climate change 2Grant supports emerging field of massive data analysis and visual analytics 2Grant supports emerging field of massive data analysis and visual analytics 3Grant supports emerging field of massive data analysis and visual analytics 4
Mouse Anti-Yersinia pestis F1 antigen Monoclonal Antibody, Unconjugated, Clone 1.F.1 from Abcam
Rabbit Anti-L Kynurenine Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-P5 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Drosophila Melanogaster Achaete protein Monoclonal Antibody, Unconjugated from Developmental Studies Hybridoma Bank
Biology Products: